Kiniksa Pharmaceuticals International, plc KNSA Software and Technology Licenses, Net
Software and Technology Licenses, Net at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's software and technology licenses, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's software and technology licenses, net?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported software and technology licenses, net of $11.16M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's software and technology licenses, net changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's software and technology licenses, net increased by 36.1% year-over-year, from $8.2M to $11.16M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's software and technology licenses, net?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's software and technology licenses, net has grown at a 15.1% compound annual growth rate (CAGR), from $5.59M to $11.31M.